Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B003 in HER2-positive recurrent or metastatic breast cancer
NCT03953833Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Apr 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B003 in breast cancer, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Maximum Tolerated Dose at 2 years, Dose-Limiting Toxicity at 21 days and 4 more. Started Apr 2019; status: completed.
02
Drugs
B003
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03953833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953833.